NCI-Designated Cancer Centers Endorse Goal of Eliminating HPV-Related Cancers

Cancers caused by the human papillomavirus (HPV) are a significant public health problem. The National Cancer Institute (NCI)-designated cancer centers fully endorse the goal of eliminating cancers caused by HPV through genderneutral HPV vaccination and evidence-based cancer screening. These practices offer a rare opportunity to prevent 12,000 cervical cancers and nearly 40,000 other HPV-related cancers (oropharyngeal, anal, penile, vulvar, and vaginal cancers) among men and women annually in the United States.

An effective and safe vaccine is available that prevents the large majority of cancer-causing HPV infections. In addition, healthcare providers can use proven methods to screen for and treat cervical pre-cancers.

Unfortunately, HPV vaccination completion rates across the U.S. remain low. According to the Centers for Disease Control and Prevention (CDC), 49.5 percent of girls and only 37.5 percent of boys, ages 13-17 years, in the U.S. completed the vaccine series in 2016. These rates are significantly lower than those for other recommended adolescent vaccinations and fall well below the nation’s goal of 80 percent coverage by the end of this decade (U.S. Department of Health and Human Service’s Healthy People 2020 objective).

Increased HPV vaccination rates combined with appropriate cervical cancer screening measures could soon eliminate cervical cancer, with other HPV-related cancers in males and females to follow. Therefore, as national leaders in cancer research and cancer care, we issue the following Call to Action in alignment with the nation’s Healthy People 2020 goals:

• Vaccination of more than 80 percent of males and females ages 13-15 by 2020; • Screen 93 percent of age-eligible females for cervical cancer by 2020; and

• Provide prompt follow up and proper treatment of females who screen positive for high grade cervical pre-cancerous lesions.

In addition, we strongly encourage:

• Young men and women up to age 26, who were not previously vaccinated, to complete the recommended HPV vaccine series;

• Health care providers to make clear and strong recommendations for HPV vaccination and cervical cancer screening; and

• The health care community to educate parents, guardians, community members, and colleagues about the goal of eliminating cancers caused by HPV in the US.

High HPV vaccination rates combined with cervical cancer screening and treatment will result in the elimination of cervical cancer in the near future and elimination of other HPV-related cancers thereafter.

The HPV vaccine PREVENTS CANCER. Make sure your loved ones are vaccinated and protected. More information is available from the CDC. Abramson Cancer Center Abramson Cancer Center Georgetown University receives income from its licensing of the HPV vaccine technology for commercialization. This statement is supported by the American Cancer Society (ACS), the American Association for Cancer Research (AACR), the American Society for Clinical Oncology (ASCO), the Prevent Cancer Foundation, the American Society for Preventive Oncology (ASPO) and the Association of American Cancer Institutes (AACI)



Lifestyle Behaviors, Energy Balance, and Chemoprevention SIG Webinar – Sept. 19, 2018, 3 p.m.

Lifestyle Behaviors, Energy Balance, and Chemoprevention SIG Webinar

Metabolomics in cancer prevention 

Sept. 19, 2018 – 3 p.m. EST

To join the webinar:

Join from a PC, Mac, iPad, iPhone or Android device:
Please click this URL to join.

Or join by phone:
Dial(for higher quality, dial a number based on your current location):
US: +1 669 900 6833 or +1 646 558 8656 or +1 877 853 5247 (Toll Free) or +1 877 369 0926 (Toll Free)
Webinar ID: 424 487 385
International numbers available:


Organizers: Elisa V. Bandera, MD, PhD, and Marji McCullough, RD, ScD

Augustin Scalbert, PhD

Head, Biomarkers Group

International Agency for Research on Cancer

Metabolomics in nutrition and cancer epidemiology


Pietro Ferrari, PhD

Head, Nutritional Methodology and Biostatistics Group

International Agency for Research on Cancer

Analytical strategies and challenges


Steven Moore, PhD, MPH

Earl Stadtman Investigator

Division of Cancer Epidemiology & Genetics, Metabolic Epidemiology BranchNational Cancer Institute

Recent cancer findings



43rd Annual Meeting: March 10-12, 2019

The 43rd Annual Meeting of the American Society of Preventive Oncology will take place March 10 through March 12, 2019 in Tampa, Florida, at the Hilton Tampa Downtown. More information to follow.

Call for Abstracts will go out in late September 2018.